A Study of an Investigational Medication for the Treatment of Secondary Hyperparathyroidism in Patients on Dialysis

Last updated: May 6, 2013
Sponsor: Amgen
Overall Status: Completed

Phase

3

Condition

Hyperparathyroidism

Parathyroid Disease

Parathyroid Disorders

Treatment

N/A

Clinical Study ID

NCT00042653
20000188
  • Ages > 18
  • All Genders

Study Summary

This 6 month study will assess an investigational medication for patients on dialysis with secondary hyperparathyroidism. The study will look at the effects on parathyroid hormone, calcium and phosphorus levels.

Eligibility Criteria

Inclusion

Patients must be receiving hemodialysis; have elevated parathyroid hormone levels; not be pregnant or nursing; and not have had a heart attack in the last 3 months.

Study Design

Total Participants: 380
Study Start date:
May 01, 2002
Estimated Completion Date:
July 31, 2003